Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Sheila R. Weiss"'
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 15:3049-3067
Naltrexone/Bupropion extended release (ER; Contrave) is an extended-release, fixed-dose combination medication of naltrexone (8 mg) and bupropion (90 mg) for patients with obesity or overweight with at least one weight-related comorbidity. Obese and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e44e255848296a1a8e534a89941e73
https://doi.org/10.2147/dmso.s381652
https://doi.org/10.2147/dmso.s381652
Autor:
Nicholas Sicignano, Sheila R. Weiss, Earl L. Goehring, Sally Tamayo, Arlene Tave, Chuntao Wu, Juhaeri Juhaeri, Vibha C. A. Desai, Judith K. Jones, Rhonda L. Bohn
Publikováno v:
Pharmacoepidemiology and Drug Safety
Purpose To compare risks of interstitial lung disease (ILD) between patients treated with dronedarone versus other antiarrhythmics. Methods Parallel retrospective cohort studies were conducted in the United States Department of Defense Military Healt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd725805e80dcd748c35f425cbaff389
https://doi.org/10.1002/pds.5233
https://doi.org/10.1002/pds.5233
Autor:
Sheila R. Weiss
Publikováno v:
JAMA. 327(20)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1689cffa3024ec92c66f37cac90ec406
https://pubmed.ncbi.nlm.nih.gov/35608588
https://pubmed.ncbi.nlm.nih.gov/35608588
Publikováno v:
Drug Safety. 36:1117-1123
The Weber effect states that adverse event (AE) reporting tends to increase in the first 2 years after a new drug is placed onto the market, peaks at the end of the second year, and then declines. However, since the Weber effect was originally descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b10525d1879d9ea1726bef2975d26f6
https://doi.org/10.1007/s40264-013-0115-x
https://doi.org/10.1007/s40264-013-0115-x
Autor:
Franklin Hendrick, Amer M. Zeidan, Xuehua Ke, Sheila R. Weiss, Amy J. Davidoff, Maria R. Baer, Steven D. Gore
Publikováno v:
Leukemia Research. 37:675-680
Erythropoiesis-stimulating agents (ESA) are used commonly to reduce symptomatic anemia in patients with myelodysplastic syndromes (MDS). We assessed population-based patterns of ESA use relative to treatment guidelines using data from the Surveillanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6195003f58be1a466214a90134b9afc
https://doi.org/10.1016/j.leukres.2013.02.021
https://doi.org/10.1016/j.leukres.2013.02.021
Publikováno v:
Health & Place. 13:404-416
To determine if emergency department utilization for pediatric respiratory illness varies across small geographic jurisdictions within a large urban city.A retrospective analysis of Maryland Health Services Cost Review Commission Emergency Department
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3265b556e3b0f2f35a2d4579fdd29dd7
https://doi.org/10.1016/j.healthplace.2006.03.004
https://doi.org/10.1016/j.healthplace.2006.03.004
Autor:
Maria R. Baer, Masayo Sato, Sheila R. Weiss, Vu H. Duong, Amy J. Davidoff, Steven D. Gore, Franklin Hendrick, Amer M. Zeidan
Introduction Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with myelodysplastic syndrome (MDS) in clinical trials. We studied the association of timing of ESA initiation, agent (epo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6035e1ada664c0367ac14b0c9968e3cf
https://europepmc.org/articles/PMC4441842/
https://europepmc.org/articles/PMC4441842/
Publikováno v:
Journal of Asthma. 43:301-306
Asthma causes pediatric morbidity throughout the US with substantial regional variability. Emergency department (ED) utilization data were studied to determine if geographic variability of pediatric asthma cases exists within a state. Records for non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c72be41a663fc9887f349227019d87b2
https://doi.org/10.1080/02770900600623255
https://doi.org/10.1080/02770900600623255
Publikováno v:
Pharmacoepidemiology and Drug Safety. 14:697-703
Purpose This study assesses the effect of the type of antidiabetic treatment on the risk of developing congestive heart failure (CHF) in type 2 diabetes. Methods The study was derived from the U.K.-based General Practice Research Database (GPRD) comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63635d1bee52eb8b9c89f27c006deb1d
https://doi.org/10.1002/pds.1069
https://doi.org/10.1002/pds.1069
Autor:
Robert J. Cluxton, Charles J Moomaw, Van Doren Hsu, Sheila R. Weiss, Ilene H. Zuckerman, Evelyn M. Rodriguez, Zili Li, Pamela C. Heaton
Publikováno v:
Pharmacoepidemiology and Drug Safety. 14:1-9
Purpose Troglitazone, the first drug of the thiazolidinediones class for type II diabetes, was first marketed in March 1997 and was removed from the U.S. market 36 months later after 90 cases of liver failure were reported despite multiple warnings c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69488861538fe628ef1bf759aa0ab302
https://doi.org/10.1002/pds.1048
https://doi.org/10.1002/pds.1048